GleamWall
中文EN

CBDY Target Group Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1586554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.1%
TTM net income YoY-155.4%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR40.5%
Net income 3-yr CAGR—

Margins

Gross margin42.0%
Operating margin—
Net margin-30.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-24.6%
ROIC (approx.)—
Asset turnover0.82x

Leverage & solvency

Liabilities / assets245.5%
Debt / equity—
Current ratio0.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.88M$6.59M
Cost of revenue$1.81M$2.87M
Gross profit$2.07M$3.73M
Interest expense$1.04M$1.15M
Pretax income-$1.36M$160,504
Income tax$0$0
Net income-$1.36M$160,504
EPS (basic)-0.000.00
EPS (diluted)-0.000.00
Weighted avg. shares (diluted)617.03M727.23M
Balance sheet
Cash & equivalents$108,800$1.88M
Receivables$446,283$77,092
Inventory$1.67M$882,279
Current assets$2.33M$3.10M
PP&E, net$3.55M$4.19M
Goodwill$260,016$247,685
Total assets$6.18M$7.57M
Current liabilities$13.38M$13.10M
Short-term debt$7.60M$7.24M
Long-term debt$7.60M$7.24M
Total debt$15.21M$14.49M
Total liabilities$14.24M$14.08M
Shareholders' equity-$8.06M-$6.51M
Net debt$15.10M$12.61M
Shares outstanding617.03M617.03M
Cash flow statement
Operating cash flow-$842,425$2.16M
Investing cash flow$81,379-$178,978
Financing cash flow-$1.06M-$730,225
Depreciation & amortization$898,403$916,213

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.